Oncology CRO Helping To Bring Cancer Therapies To Patients
Niche CRO with a difference
Catalyst Oncology is a niche oncology CRO devoting time, energy, and capital to supporting biotechs in bringing next-generation therapies to patients in need. Oncology clinical research is complex, demanding, and continually evolving. Bringing effective therapies to proof-of-concept and then to market as fast as possible is our passion because every second counts for patients with cancer and their families.
Exclusively biotech
Built to work exclusively with biotechs, our flexible processes and approach allow us to listen first, align goals, and execute with an eye to rapid shifts when protocols amend or breakthrough designations move a product straight from Phase I to registration.
Seasoned oncology experts
With a minimum requirement of 5+ years of oncology experience for key roles, our oncology niche guarantees you a seasoned team across all functions.
A Transparent, People-First Culture
Our people-first culture ensures we are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention guarantee program continuity, increased efficiency, and happy investigative sites.
Flexible solutions and best-in-class technologies
- Full-service, resourcing, and functional service provider (FSP) options
- Technology-enabled investments not typically seen with a company our size
- Partnerships to leverage recent industry breakthroughs
Data-centric approach
- Cross-functional oncology approach to quality data
- Proprietary clinical analytics platform
- 70% oncology forms and 120+ standard displays for rapid database deployment and protocol-specific analysis
Site network model
- Centralized Site Services team
- Streamlined site interactions to reduce site burden
- Rapid site activations
- Next-gen site network
Emerging targeted and immuno-oncology focus
- Complex study designs and endpoints
- Targeted therapies: biomarker and NGS selection
- IO: bispecifics, gene therapy, cellular therapy
- Experience in CAR-T since 2015
Next-gen oncology experience
Working largely in early- to mid-phase development across a range of both solid and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.
